The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis

Ramin Jalili ¹ , Mohammad Hossein Somi ², Hossein Hosseinifard ³, Fatemeh Salehnia ³, Morteza Ghojazadeh ³, Nima Makhdami ⁴, Masoud Shirmohammadi ⁵ *

Cited by CrossRef: 6

1- Kim S, Lee S, Yu S. Study of lipid proton difference evaluation via 9.4T MRI analysis of fatty liver induced by exposure to methionine and choline-deficient (MCD) diet and high-fat diet (HFD) in an animal model. Chemistry and Physics of Lipids. 2022;242:105164 [Crossref]

2- Park M, Kim H, Kim M, Kim K. Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis. Clin Mol Hepatol. 2023;29(3):693 [Crossref]

3- Hartl L, Elias J, Prager G, Reiberger T, Unger L. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. WJG. 2021;27(19):2281 [Crossref]

4- Yan C, Tian D, Zhang C, Zhang Q, Sun Y. Evaluation of blood cellular and biochemical parameters in rats under a chronic hypoxic environment at high altitude. Annals of Medicine. 2023;55(1):898 [Crossref]

5- Fang X, Wang C, Deng J, Qi X. Statins for treatment of fatty liver disease: Recent advances. WCJD. 2023;31(16):659 [Crossref]